정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.
PEN는 Penumbra, Inc.를 나타내며, 주가 $317.78($12.5B 시가총액)의 헬스케어 기업입니다. 펀더멘털, 기술적, 심리 요인 전반에서 94/100의 높은 신뢰도 점수를 기록합니다.
Penumbra, Inc. is a global medical device company specializing in innovative therapies for neurovascular and vascular diseases. Their aspiration-based thrombectomy systems and embolization technologies address critical unmet needs in stroke and peripheral intervention.
MoonshotScore는 투명한 0-100 등급입니다. 미국 상장 보통주는 사업 품질, 재무 안전성, 밸류에이션, 성장 지속성, 모멘텀의 5대 축에 걸쳐 섹터 동종 기업과 비교해 점수가 매겨지며, ETF, OTC 및 해외 상장 종목은 9개 시그널 레거시 모델을 사용합니다. 이는 금융 조언이 아닌 교육 및 심층 실사를 위해 만들어졌습니다. 방법론
기업 개요
요약:
Penumbra, Inc. is a medical device company focused on neurovascular and peripheral vascular therapies, offering innovative aspiration and embolization technologies.
With a strong emphasis on stroke treatment and a global market presence, Penumbra distinguishes itself through its proprietary device designs and direct sales approach.
PEN는 무엇을 하는 회사인가요?
Penumbra, Inc., founded in 2004 and headquartered in Alameda, California, is a global medical device company that designs, develops, manufactures, and markets innovative therapies and products focused on addressing challenging medical conditions and significant clinical needs.
The company's initial focus was on neurovascular intervention, specifically stroke treatment, with its Penumbra System, an aspiration-based thrombectomy system designed to remove blood clots from the brain. Over time, Penumbra has expanded its 제품 포트폴리오 to include neurovascular embolization systems, such as the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil, used to treat aneurysms and other neurovascular lesions. Additionally, the company offers neurovascular access systems like Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM, facilitating access for various neurovascular therapies. Penumbra has also diversified into peripheral vascular interventions with its Indigo System, an aspiration-based thrombectomy system for removing clots from peripheral arteries and veins. The company's product offerings extend to neurosurgical aspiration tools (Artemis Neuro Evacuation Device), detachable embolic coil systems (Ruby Coil and Ruby LP), microcatheters (LANTERN), and occlusion devices (POD). More recently, Penumbra has ventured into immersive computer-based technologies and immersive therapeutics with its Real Immersive System, targeting health, motor function, and cognition. Penumbra distributes its products through a combination of direct sales organizations and distributors, serving hospitals and physicians worldwide.
PEN의 투자 테제는 무엇인가요?
PEN는 어떤 산업에서 운영되고 있나요?
Penumbra operates in the dynamic medical device industry, specifically within the neurovascular and peripheral vascular segments. The market for stroke treatment and vascular interventions is growing due to an aging population and increasing prevalence of vascular diseases.
Competition includes established players like BAX: Baxter International Inc. and GMED: Globus Medical, Inc., as well as specialized companies focusing on thrombectomy and embolization technologies. Penumbra's innovative 제품 포트폴리오 and direct sales approach position it to capture 시장 점유율 in this 경쟁 환경.
PEN의 성장 기회는 무엇인가요?
- Expansion of the Penumbra System for Stroke Intervention: The market for acute stroke treatment is substantial, driven by the high incidence of stroke and the need for rapid intervention. Penumbra's aspiration-based thrombectomy system offers a 매력적인 solution for removing blood clots and restoring blood flow to the brain. Continued adoption of the Penumbra System in hospitals and stroke centers represents a significant 성장 기회. The global stroke management market is projected to reach $35 billion by 2028, providing a large addressable market for Penumbra.
- Growth in Peripheral Vascular Interventions: Penumbra's Indigo System addresses the growing need for effective thrombectomy solutions in peripheral arteries and veins. The increasing prevalence of peripheral artery disease (PAD) and venous thromboembolism (VTE) is driving demand for minimally invasive interventions. Penumbra's focus on aspiration-based thrombectomy offers a 경쟁 우위 in this market. The peripheral vascular device market is expected to reach $15 billion by 2027, presenting a substantial 성장 기회 for Penumbra.
- Development and Commercialization of New Products: Penumbra's commitment to innovation and product development is a key driver of growth. The company's pipeline includes new devices and technologies for neurovascular and peripheral vascular applications. Successful development and commercialization of these products will expand Penumbra's addressable market and strengthen its competitive position. Penumbra's investment in R&D is expected to yield new 제품 출시es in the coming years, contributing to 매출 성장.
- Expansion into Immersive Therapeutics: Penumbra's Real Immersive System represents a new 성장 기회 in the emerging field of immersive therapeutics. This technology has the potential to improve health, motor function, and cognition in patients with neurological disorders. The market for immersive therapeutics is growing rapidly, driven by increasing awareness of the benefits of virtual reality and augmented reality in healthcare. Penumbra's early entry into this 시장 지위s it to capitalize on this trend.
- Geographic Expansion: Penumbra's international presence is growing, with sales in 유럽, 아시아, and other regions. Expanding its geographic reach will allow Penumbra to access new markets and increase its revenue. The company's direct sales organization and distributor network provide a strong foundation for international expansion. Penumbra is targeting key international markets with high growth potential, such as 중국 and 인도, to drive future 매출 성장.
- 시가총액 of $12.5B 반영합니다 investor confidence in Penumbra's growth prospects within the medical device industry.
- 주가수익비율(P/E) of 79.95 나타냅니다 a premium valuation, suggesting high expectations for future earnings growth.
- 매출총이익률 of 67.4% 보여줍니다 Penumbra's ability to maintain strong profitability in its product lines.
- 순이익률 of 11.8% 보여줍니다 efficient operational management and cost control.
- 베타 of 0.84 suggests lower 변동성 compared to the overall market, potentially appealing to risk-averse investors.
PEN는 어떤 제품과 서비스를 제공하나요?
- Designs and develops medical devices for neurovascular and vascular diseases.
- Manufactures aspiration-based thrombectomy systems for stroke treatment.
- Offers neurovascular embolization systems for treating aneurysms.
- Provides neurovascular access systems for intracranial access.
- Develops neurosurgical aspiration tools for tissue and fluid removal.
- Markets detachable embolic coil systems for peripheral embolization.
- Offers immersive computer-based technologies for therapeutic applications.
PEN는 어떻게 수익을 창출하나요?
- Designs, develops, and manufactures medical devices in-house.
- Sells products through direct sales organizations and distributors.
- Generates revenue from the sale of aspiration-based thrombectomy systems.
- Revenue from neurovascular embolization systems and access systems.
- 반복 수익 from disposable components and accessories.
- Hospitals and stroke centers.
- Neurosurgeons and interventional radiologists.
- Vascular surgeons.
- Rehabilitation centers.
- 독자적 기술 in aspiration-based thrombectomy.
- Strong brand reputation in neurovascular intervention.
- Direct sales organization with deep customer relationships.
- Extensive patent portfolio protecting key products.
- High 전환 비용 for hospitals and physicians due to training and experience.
PEN 주가를 상승시킬 수 있는 요인은 무엇인가요?
- Upcoming: New 제품 출시es in neurovascular and peripheral vascular intervention.
- Ongoing: Continued adoption of the Penumbra System for stroke treatment.
- Ongoing: Expansion into new geographic markets.
- Ongoing: Positive 임상시험 results for new products.
PEN의 주요 리스크는 무엇인가요?
- Potential: Competition from established medical device companies.
- Potential: 규제 리스크s and product recalls.
- Potential: Changes in reimbursement policies.
- Ongoing: Product liability claims.
- Ongoing: Technological obsolescence.
PEN의 핵심 강점은 무엇인가요?
- Innovative 제품 포트폴리오 in neurovascular and vascular intervention.
- Strong brand reputation and clinical evidence.
- Direct sales organization with deep customer relationships.
- High 매출총이익률s and profitability.
PEN의 약점은 무엇인가요?
- Reliance on a limited number of key products.
- Exposure to 규제 리스크s and product recalls.
- Competition from larger medical device companies.
- High valuation relative to earnings.
PEN에게 어떤 기회가 있나요?
- Expansion into new therapeutic areas, such as immersive therapeutics.
- Geographic expansion into 신흥시장.
- Development and commercialization of new products.
- Strategic acquisitions to expand 제품 포트폴리오.
회사 프로필
- CEO: Adam Elsesser
- 본사: Alameda, CA, US
- 직원 수: 4,500
- IPO 연도: 2015
AI 인사이트
PEN의 경쟁사는 누구인가요?
PEN를 가격, 시가총액, AI MoonshotScore 기준으로 5개 동종 업체와 비교합니다。
| 회사 | 가격 | 변동 | 시가총액 | MoonshotScore |
|---|---|---|---|---|
| GMED Globus Medical, Inc. | $73.63 | +0.10% | $9.93B | 95 |
| ALGN Align Technology, Inc. | $150.72 | -1.44% | $10.8B | 82 |
| DVA DaVita Inc. | $181.33 | -0.92% | $11.6B | 74 |
| BAX Baxter International Inc. | $24.18 | -0.86% | $12.5B | 53 |
| HSIC Henry Schein, Inc. | $87.90 | +0.69% | $10.0B | 70 |
AI 점수 제공: Stock Expert AI · 가격 데이터: FMP / Yahoo Finance
재무
기본 분석 스냅샷
FMP 재무 데이터 및 정량적 분석 기반 · FY 2025
애널리스트 컨센서스
컨센서스 목표가: $320.00 (2026년 8월 29일)상승 여력: +0.7%
Financial Modeling Prep가 집계한 PEN의 종합 매수/보유/매도 추천.
최신 뉴스
-
Starlab opens microgravity research proposals for ISS flights
All News · 약 9시간 전
-
Trump dismisses AI extinction risks as more than a dozen OpenAI, Anthropic insiders call for a slowdown
CNBC · 약 10시간 전
-
Why fears of AI self-improvement are causing ‘existential’ concerns at Anthropic and OpenAI
CNBC · 약 10시간 전
-
IEA warns of ‘lost period’ in global oil demand
International homepage · 약 11시간 전
경영진
CEO: Adam Elsesser
질문 및 답변
What does Penumbra, Inc. do?
Penumbra, Inc. is a global medical device company focused on developing and marketing innovative therapies for neurovascular and peripheral vascular diseases.
The company's primary focus is on aspiration-based thrombectomy systems, which are used to remove blood clots from the brain and peripheral vessels.
What do analysts say about PEN stock?
애널리스트 컨센서스 on PEN stock is generally positive, reflecting optimism about the company's growth prospects in the neurovascular and peripheral vascular markets.
Key valuation metrics, such as the 주가수익비율(P/E) of 79.95, suggest that the stock is trading at a premium, indicating high expectations for future earnings growth.
What are the main risks for PEN?
Penumbra faces several key risks, including competition from established medical device companies with greater resources and broader 제품 포트폴리오s. The company is also subject to 규제 리스크s, including the potential for product recalls and changes in reimbursement policies.
Product liability claims are another significant risk, given the nature of Penumbra's products and their use in critical medical procedures.
How does Penumbra, Inc. manage patent expiration risks?
As a medical device company, Penumbra, Inc. faces patent expiration risks that could impact its 수익원s. To mitigate these risks, Penumbra employs several strategies, including continuously innovating and developing new products and technologies to replace those facing patent expiration.
The company also actively manages its patent portfolio, seeking to extend 특허 보호 through improvements and modifications to existing products.
What 수익원s does Penumbra, Inc. have in healthcare?
Penumbra, Inc.'s 수익원s are primarily derived from the sale of its medical devices used in neurovascular and peripheral vascular procedures.
The company's main revenue drivers include its aspiration-based thrombectomy systems, such as the Penumbra System for stroke treatment and the Indigo System for peripheral vascular interventions.
면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.
데이터는 정보 제공만을 목적으로 제공됩니다.